These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31171598)

  • 1. Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors.
    Pereira PMR; Mandleywala K; Ragupathi A; Carter LM; Goos JACM; Janjigian YY; Lewis JS
    J Nucl Med; 2019 Nov; 60(11):1569-1578. PubMed ID: 31171598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
    Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
    Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging of HER2 with [
    Massicano AVF; Lee S; Crenshaw BK; Aweda TA; El Sayed R; Super I; Bose R; Marquez-Nostra BV; Lapi SE
    Cancer Biother Radiopharm; 2019 May; 34(4):209-217. PubMed ID: 30676778
    [No Abstract]   [Full Text] [Related]  

  • 4. Immuno-PET Detects Antibody-Drug Potency on Coadministration with Statins.
    Brown EL; Shmuel S; Mandleywala K; Panikar SS; Berry NK; Rao Y; Zidel A; Lewis JS; Pereira PMR
    J Nucl Med; 2023 Oct; 64(10):1638-1646. PubMed ID: 37385676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers.
    Rao Y; Samuels Z; Carter LM; Monette S; Panikar SS; Pereira PMR; Lewis JS
    Proc Natl Acad Sci U S A; 2023 Apr; 120(14):e2220413120. PubMed ID: 36972439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.
    Janjigian YY; Viola-Villegas N; Holland JP; Divilov V; Carlin SD; Gomes-DaGama EM; Chiosis G; Carbonetti G; de Stanchina E; Lewis JS
    J Nucl Med; 2013 Jun; 54(6):936-43. PubMed ID: 23578997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward Understanding the Binding Synergy of Trastuzumab and Pertuzumab to Human Epidermal Growth Factor Receptor 2.
    Sharma R; Kumbhakar M; Mukherjee A
    Mol Pharm; 2021 Dec; 18(12):4553-4563. PubMed ID: 34757737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo.
    Guan SS; Wu CT; Chiu CY; Luo TY; Wu JY; Liao TZ; Liu SH
    J Transl Med; 2018 Jun; 16(1):168. PubMed ID: 29921305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer.
    Wei R; Zhang W; Yang F; Li Q; Wang Q; Liu N; Zhu J; Shan Y
    J Transl Med; 2024 Jul; 22(1):641. PubMed ID: 38982548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
    McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
    J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and preclinical studies of
    Lam K; Chan C; Reilly RM
    MAbs; 2017 Jan; 9(1):154-164. PubMed ID: 27813707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models.
    Yamashita-Kashima Y; Iijima S; Yorozu K; Furugaki K; Kurasawa M; Ohta M; Fujimoto-Ouchi K
    Clin Cancer Res; 2011 Aug; 17(15):5060-70. PubMed ID: 21700765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer.
    Jiang D; Im HJ; Sun H; Valdovinos HF; England CG; Ehlerding EB; Nickles RJ; Lee DS; Cho SY; Huang P; Cai W
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1296-1305. PubMed ID: 28265738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts.
    Marquez BV; Ikotun OF; Zheleznyak A; Wright B; Hari-Raj A; Pierce RA; Lapi SE
    Mol Pharm; 2014 Nov; 11(11):3988-95. PubMed ID: 25058168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of
    Sharma R; Mukherjee A; Kumar A; Sarma HD
    Cancer Biother Radiopharm; 2024 Feb; 39(1):64-74. PubMed ID: 38363819
    [No Abstract]   [Full Text] [Related]  

  • 16. Pertuzumab in gastrointestinal cancer.
    Oh DY; Bang YJ
    Expert Opin Biol Ther; 2016; 16(2):243-53. PubMed ID: 26619359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using
    Ulaner GA; Lyashchenko SK; Riedl C; Ruan S; Zanzonico PB; Lake D; Jhaveri K; Zeglis B; Lewis JS; O'Donoghue JA
    J Nucl Med; 2018 Jun; 59(6):900-906. PubMed ID: 29146695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer neovasculature-targeted near-infrared photoimmunotherapy (NIR-PIT) for gastric cancer: different mechanisms of phototoxicity compared to cell membrane-targeted NIR-PIT.
    Nishimura T; Mitsunaga M; Ito K; Kobayashi H; Saruta M
    Gastric Cancer; 2020 Jan; 23(1):82-94. PubMed ID: 31302791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
    Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
    J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired resistance to trastuzumab/pertuzumab or to T-DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728.
    Irie H; Kawabata R; Fujioka Y; Nakagawa F; Itadani H; Nagase H; Ito K; Uchida J; Ohkubo S; Matsuo K
    Cancer Sci; 2020 Jun; 111(6):2123-2131. PubMed ID: 32248641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.